The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.

IF 1 4区 医学 Q4 NEUROSCIENCES
Qiang Liu, Haiping Wang, Shengyin Lv, Yanyan Zhao, Yabin Zheng, Guanyu Li, Wei Wang
{"title":"The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.","authors":"Qiang Liu, Haiping Wang, Shengyin Lv, Yanyan Zhao, Yabin Zheng, Guanyu Li, Wei Wang","doi":"10.62641/aep.v52i6.1711","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.</p><p><strong>Methods: </strong>This retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023. Based on the treatment approaches, the patients were categorized into the control group (n = 61) and the observation group (n = 59). The control group received oral levodopa/benserazide tablets, while the observation group was treated with levodopa/benserazide tablets combined with pramipexole. The two experimental groups were assessed and compared across several parameters, including PD symptoms [Unified Parkinson's Disease Rating Scale (UPDRS)], cognitive function [Montreal Cognitive Assessment (MoCA)], the levels of plasma monoamine neurotransmitters, and serum GDF-15 and Ang-1 levels.</p><p><strong>Results: </strong>The response rate to treatment was more significant in the observation group (96.55%) compared to the control group (87.93%, p = 0.162). Post-treatment, both groups demonstrated a decline in their UPDRS and overall scores, with the observation group indicating substantially lower scores than the control group (p < 0.05). Furthermore, both groups showed improvements in MoCA scores, with the observation group exhibiting higher scores than the control group (p < 0.05). Similarly, we observed significantly increased dopamine, 5-hydroxytryptamine, and norepinephrine levels in both groups, with the observation group showing a more pronounced increase (p < 0.05). Additionally, we observed a significant decrease in serum GDF-15 levels and an increase in Ang-1 levels across both groups after treatment. However, the observation group exhibited lower GDF-15 levels and higher Ang-1 levels than the control group (p < 0.05).</p><p><strong>Conclusions: </strong>The combined use of levodopa/benserazide and pramipexole proves beneficial for managing PD. This therapeutic regimen can improve cognitive abilities and plasma monoamine neurotransmitter levels in PD patients, reduce brain tissue damage and decrease serum levels of GDF-15.</p>","PeriodicalId":7251,"journal":{"name":"Actas espanolas de psiquiatria","volume":"52 6","pages":"769-776"},"PeriodicalIF":1.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636542/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas espanolas de psiquiatria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62641/aep.v52i6.1711","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Parkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.

Methods: This retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023. Based on the treatment approaches, the patients were categorized into the control group (n = 61) and the observation group (n = 59). The control group received oral levodopa/benserazide tablets, while the observation group was treated with levodopa/benserazide tablets combined with pramipexole. The two experimental groups were assessed and compared across several parameters, including PD symptoms [Unified Parkinson's Disease Rating Scale (UPDRS)], cognitive function [Montreal Cognitive Assessment (MoCA)], the levels of plasma monoamine neurotransmitters, and serum GDF-15 and Ang-1 levels.

Results: The response rate to treatment was more significant in the observation group (96.55%) compared to the control group (87.93%, p = 0.162). Post-treatment, both groups demonstrated a decline in their UPDRS and overall scores, with the observation group indicating substantially lower scores than the control group (p < 0.05). Furthermore, both groups showed improvements in MoCA scores, with the observation group exhibiting higher scores than the control group (p < 0.05). Similarly, we observed significantly increased dopamine, 5-hydroxytryptamine, and norepinephrine levels in both groups, with the observation group showing a more pronounced increase (p < 0.05). Additionally, we observed a significant decrease in serum GDF-15 levels and an increase in Ang-1 levels across both groups after treatment. However, the observation group exhibited lower GDF-15 levels and higher Ang-1 levels than the control group (p < 0.05).

Conclusions: The combined use of levodopa/benserazide and pramipexole proves beneficial for managing PD. This therapeutic regimen can improve cognitive abilities and plasma monoamine neurotransmitter levels in PD patients, reduce brain tissue damage and decrease serum levels of GDF-15.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Actas espanolas de psiquiatria
Actas espanolas de psiquiatria 医学-精神病学
CiteScore
1.70
自引率
6.70%
发文量
46
审稿时长
>12 weeks
期刊介绍: Actas Españolas de Psiquiatría publicará de manera preferente trabajos relacionados con investigación clínica en el área de la Psiquiatría, la Psicología Clínica y la Salud Mental.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信